Treatment of hair loss disorders with deuterated JAK inhibitors
Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
1. A method of treating a hair loss disorder in a mammalian subject, the method comprising administering to the subject 16 mg/day or 24 mg/day of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.
2. The method of claim 1 , wherein the hair loss disorder is alopecia areata.
3. The method of any one of claim 1 , wherein the compound is administered orally.
4. The method of claim 1 , wherein the compound is administered in a pharmaceutical formulation which is a tablet.
5. The method of claim 1 , wherein the compound is administered once a day.
6. The method of claim 1 , wherein the compound is administered twice a day.
7. The method of claim 1 , wherein in Compound (I), any atom not designated as deuterium is present at its natural isotopic abundance.
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and 8 mg or 12 mg of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.
9. A method of treating a hair loss disorder in a mammalian subject, the method comprising administering to the subject twice a day 8 mg of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.
10. The method of claim 9 , wherein Compound (I) is administered as 10.5 mg of the phosphate salt twice per day.
11. A method of treating a hair loss disorder in a mammalian subject, the method comprising administering to the subject twice per day 12 mg of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.
12. The method of claim 11 , wherein Compound (I) is administered as 15.8 mg of the phosphate salt twice per day.
13. The method of claim 1 , wherein each position in Compound (I) designated specifically as deuterium has at least 97% incorporation of deuterium.
14. The method of claim 1 , wherein the step of administering comprises administering to the subject 8 mg twice per day or 12 mg twice per day of Compound (I).
15. The method of claim 9 , wherein the hair loss disorder is alopecia areata.
16. The method of claim 9 , wherein the compound is administered orally.
17. The method of claim 9 , wherein each position in Compound (I) designated specifically as deuterium has at least 97% incorporation of deuterium.
18. The method of claim 11 , wherein the hair loss disorder is alopecia areata.
19. The method of claim 11 , wherein compound is administered orally.
20. The method of claim 11 , wherein each position in Compound (I) designated specifically as deuterium has at least 97% incorporation of deuterium.
21. The method of claim 14 , wherein the subject is a human.